1. More Than Meets the Eye: Identifying Who Is at Risk for NASH

2. NAFLD: Hepatic Manifestation of Metabolic Syndrome

3. NASH: From Steatosis to Cirrhosis

4. Prevalence of NAFLD Growing in Parallel With Obesity and Metabolic Syndrome

5. Patients at Risk for NASH How Do You Spot Them?

6. NASH in the Asia-Pacific Region

7. Case 1: 32-Year-Old Caucasian Man With Fatty Liver Seen In Ultrasound

8. Case 2: 60-Year-Old Hispanic Man With Well-Controlled Diabetes

9. Stratifying Risk for NASH It's Not All About Lab Values

10. The Genetic Component of NASH I148M PNPLA3 and Progressive Liver Disease

11. NASH Is a Phenotype Multi-Hit Pathogenesis

12. Ballooning: A Histologic Feature of NAFL

13. Natural History of NAFLD

14. HCC in NAFLD: Occurs In Patients With and Without Cirrhosis

15. NAFLD/NASH-Associated HCC Tumor Burden Is High

16. Ultrasound in NASH Not an Optimal Tool

17. NASH: Fast Becoming Leading Indication for Liver Transplantation in the United States

18. Progression of NAFLD Is Not Linear Fibrosis Is a Moving Target

19. NAFLD: Factors Related to Progression vs Regression

20. Using Clinical Parameters to Predict Outcomes

21. Biomarkers for NASH: What's In the Toolkit Now?

22. Why Is Assessment of Fibrosis vs NASH Important?

23. Patient- and Healthcare-Related Outcomes

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)